Toxin-based targeted therapy for malignant brain tumors.

dc.contributor.author

Chandramohan, Vidyalakshmi

dc.contributor.author

Sampson, John H

dc.contributor.author

Pastan, Ira

dc.contributor.author

Bigner, Darell D

dc.date.accessioned

2022-09-01T13:32:34Z

dc.date.available

2022-09-01T13:32:34Z

dc.date.issued

2012-01

dc.date.updated

2022-09-01T13:32:33Z

dc.description.abstract

Despite advances in conventional treatment modalities for malignant brain tumors-surgery, radiotherapy, and chemotherapy-the prognosis for patients with high-grade astrocytic tumor remains dismal. The highly heterogeneous and diffuse nature of astrocytic tumors calls for the development of novel therapies. Advances in genomic and proteomic research indicate that treatment of brain tumor patients can be increasingly personalized according to the characteristics of the targeted tumor and its environment. Consequently, during the last two decades, a novel class of investigative drug candidates for the treatment of central nervous system neoplasia has emerged: recombinant fusion protein conjugates armed with cytotoxic agents targeting tumor-specific antigens. The clinical applicability of the tumor-antigen-directed cytotoxic proteins as a safe and viable therapy for brain tumors is being investigated. Thus far, results from ongoing clinical trials are encouraging, as disease stabilization and patient survival prolongation have been observed in at least 109 cases. This paper summarizes the major findings pertaining to treatment with the different antiglioma cytotoxins at the preclinical and clinical stages.

dc.identifier.issn

1740-2522

dc.identifier.issn

1740-2530

dc.identifier.uri

https://hdl.handle.net/10161/25632

dc.language

eng

dc.publisher

Hindawi Limited

dc.relation.ispartof

Clinical & developmental immunology

dc.relation.isversionof

10.1155/2012/480429

dc.subject

Humans

dc.subject

Glioma

dc.subject

Brain Neoplasms

dc.subject

Recombinant Fusion Proteins

dc.subject

Immunotoxins

dc.subject

Antigens, Neoplasm

dc.subject

Prognosis

dc.subject

Survival Analysis

dc.subject

Proteomics

dc.subject

Clinical Trials as Topic

dc.subject

Molecular Targeted Therapy

dc.subject

Tumor Microenvironment

dc.subject

Precision Medicine

dc.title

Toxin-based targeted therapy for malignant brain tumors.

dc.type

Journal article

duke.contributor.orcid

Chandramohan, Vidyalakshmi|0000-0002-0653-3014

duke.contributor.orcid

Sampson, John H|0000-0002-0104-7658

duke.contributor.orcid

Bigner, Darell D|0000-0001-5548-4899

pubs.begin-page

480429

pubs.organisational-group

Duke

pubs.organisational-group

Pratt School of Engineering

pubs.organisational-group

School of Medicine

pubs.organisational-group

Basic Science Departments

pubs.organisational-group

Clinical Science Departments

pubs.organisational-group

Institutes and Centers

pubs.organisational-group

Immunology

pubs.organisational-group

Biomedical Engineering

pubs.organisational-group

Orthopaedic Surgery

pubs.organisational-group

Pathology

pubs.organisational-group

Radiation Oncology

pubs.organisational-group

Surgery

pubs.organisational-group

Duke Cancer Institute

pubs.organisational-group

Neurosurgery

pubs.organisational-group

Neurosurgery, Neuro-Oncology

pubs.publication-status

Published

pubs.volume

2012

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Toxin-based targeted therapy for malignant brain tumors.pdf
Size:
1.35 MB
Format:
Adobe Portable Document Format